{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenovirus+Infection&page=2", "query": { "condition": "Adenovirus Infection", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenovirus+Infection&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T02:05:21.626Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02231853", "title": "Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "CML (Chronic Myelogenous Leukemia)", "MDS (Myelodysplastic Syndrome)", "Acute Lymphoblastic Leukemia", "AML (Acute Myelogenous Leukemia)" ], "interventions": [ { "name": "MVST", "type": "BIOLOGICAL" }, { "name": "MVSTr", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 12, "start_date": "2014-09-03", "completion_date": "2017-12-29", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231853" }, { "nct_id": "NCT03329248", "title": "QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "lovaza", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2017-11-06", "completion_date": "2019-11-01", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329248" }, { "nct_id": "NCT00870987", "title": "Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malaria" ], "interventions": [ { "name": "DNA vaccine prime", "type": "BIOLOGICAL" }, { "name": "adenovirus type 5 vaccine boost", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 82, "start_date": "2009-05", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00870987" }, { "nct_id": "NCT01103687", "title": "Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ad26.ENVA.01 (rAd26)", "type": "BIOLOGICAL" }, { "name": "Placebo Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 24, "start_date": "2010-07", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-09-08", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01103687" }, { "nct_id": "NCT00080106", "title": "Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MRK Ad5 HIV-1 gag vaccine", "type": "BIOLOGICAL" }, { "name": "Vaccine placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 114, "start_date": "2004-06", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 27, "location_summary": "Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080106" }, { "nct_id": "NCT02315703", "title": "Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "MVA-Mosaic", "type": "BIOLOGICAL" }, { "name": "gp140 DP Low-dose", "type": "BIOLOGICAL" }, { "name": "gp140 DP High-dose", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 393, "start_date": "2014-12-22", "completion_date": "2022-03-28", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 5, "location_summary": "Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315703" }, { "nct_id": "NCT03964415", "title": "A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C and Mosaic gp140 HIV bivalent vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 3900, "start_date": "2019-10-31", "completion_date": "2023-08-10", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 20, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03964415" }, { "nct_id": "NCT00004225", "title": "Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Ad5CMV-p53 gene", "type": "BIOLOGICAL" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-07-07", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004225" }, { "nct_id": "NCT02197169", "title": "DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma or Gliosarcoma" ], "interventions": [ { "name": "Single intratumoral injection of DNX-2401", "type": "DRUG" }, { "name": "Interferon-gamma", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DNAtrix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2014-09-11", "completion_date": "2018-03-15", "has_results": false, "last_update_posted_date": "2018-07-16", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 4, "location_summary": "Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02197169" }, { "nct_id": "NCT05686798", "title": "Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma of Brain", "Astrocytoma", "Malignant Astrocytoma", "Brain Tumor", "Glioma", "Brain Cancer", "Glioblastoma", "Glioblastoma Multiforme", "GBM" ], "interventions": [ { "name": "Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-11-29", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-06-11T02:05:21.626Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05686798" } ] }